Prof. Mark Dawson is a clinician-scientist at the Peter MacCallum Cancer Centre. He is the program head of the Translational Haematology Program, Group leader of the Cancer Epigenetics Laboratory and Consultant Haematologist in the Department of Haematology. His research interest is studying cancer biology to identify new treatments that improve the outcome for patients with cancer. He is a fellow of the Royal Australasian College of Physicians and Royal College of Pathologists of Australasia. After completing his clinical training in Melbourne, Australia he was awarded the prestigious John Monash Scholarship and Cambridge Commonwealth Trust Fellowship, which he used to complete his PhD at the University of Cambridge. Following his PhD, he was awarded the inaugural Wellcome Trust Beit Prize Fellowship to pursue his research into a molecular understanding of leukaemia stem cells. This research identified a new therapeutic strategy for acute myeloid leukaemia and helped set the platform for clinical trials around the world with a first in class epigenetic therapy. His research has been published in world leading journals including Nature, Cell, Science and New England Journal of Medicine. He is currently a Professor in the Sir Peter MacCallum Department of Oncology and Centre of Cancer Research at the University of Melbourne. He is also the Senior Research Fellow for the Leukaemia Foundation of Australia and a Howard Hughes Medical Institute International Research Scholar.